Results 111 to 120 of about 20,250 (180)

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma. [PDF]

JCO Precis Oncol
Milewski D, Fallatah A, Groff M, Rahmy A, Khan SR, Okafor C, Glassberg B, Chou HC, Heselmeyer-Haddad K, Wangsa D, Wangsa D, Kim Y, Isanogle K, Song Y, Zhang X, Thomas C, Difilippantonio S, Park JI, Wei JS, Hawley RG, Glod J, Khan J.   +21 more
europepmc   +1 more source

Incidence and management of pyrexia syndrome in patients treated with dabrafenib and trametinib: a retrospective study. [PDF]

Support Care Cancer
Komisarof J, Menon J, Andrzejewski A, Mulford D.   +3 more
europepmc   +1 more source

Novel uveal melanoma patient-derived cell line and organoid models show increased treatment resistance compared with commercially available cell lines. [PDF]

Melanoma Res
Dalvin LA, Burr SD, Miley DR, Ong H, Armitage JA.   +4 more
europepmc   +1 more source

Clinical outcomes in older adults with advanced thyroid cancer. [PDF]

Oncologist
Janse van Rensburg HJ, Xiao T, Lajkosz K, Sugumar V, Alibhai SMH, Goldstein D, Mesci A, Barron CC, Ma LX.   +8 more
europepmc   +1 more source

Rebound regrowth phenomenon in patients with pediatric low-grade gliomas treated with MAPK inhibitors - a systematic review. [PDF]

Oncol Rev
Styczewska M, Lyzinska W, Krawczyk MA, Bien E.   +3 more
europepmc   +1 more source

MEK inhibition in adult patients with pilocytic astrocytomas. [PDF]

NPJ Precis Oncol
Rounis K, Delgado AF, Illies C, Shamikh A, Wangerid T, Jensdottir M, Bartek J, Persson O, Hietala MA, Friesland S, Carstens H, Stragliotto G.   +11 more
europepmc   +1 more source

Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses. [PDF]

Front Immunol
Wang X, Liu L, Li F, Da Y, Hu F, Qi X, Pan Y, Jiang M, Hou P, Yang J.   +9 more
europepmc   +1 more source

BRAF ^<b>V600E</b> Metastatic Synovial Sarcoma Treated with BRAF & MEK Inhibitors Achieves Complete Response. A Case Report & Literature Review. [PDF]

Oncol Res
Burg D, Babkoff A, Or O, Olshinka N, Demma JA, Adila M, Wygoda M, Blumenfeld P, Diment J, Galiner M, Azraq Y, Katz D, Reissman P, Ostrowicki S, Sebbag G, Elkhateeb N, Moshe AH, Jaber D, Hollander A, Rubin L, Zick A.   +20 more
europepmc   +1 more source

BRAF V600E-mutated metastatic Wilms tumor with complete response to targeted RAF/MEK inhibition: a post-treatment follow-up case report. [PDF]

Front Oncol
Slika I, Edwards CK, Cohen KJ, Friedman AD, Pratilas CA, Odeniyide P.   +5 more
europepmc   +1 more source

A Case of Immunotherapy Response to BRAF^V600E-Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy. [PDF]

Cancer Rep (Hoboken)
Okayama Y, Tokito T, Shiraishi S, Takaki R, Tsuneyoshi S, Yamada H, Nishiyama M, Sueyasu Y, Hoshino T.   +8 more
europepmc   +1 more source